We report the case of a 55-year-old male European who became septic after he returned from a four-week holiday to Uganda. Soon after, he was diagnosed with severe falciparum malaria and developed multi-organ failure. Due to the worsening condition of the patient, drotrecogin alfa (activated) was started, soon after which the patient's condition significantly improved. He returned home on day 36 after admission, without neurologic sequelae.
Looking at those few cases of severe forms of malaria where drotrecogin alfa (activated) was successfully used, it should at least be considered for administration in patients with severe falciparum malaria with disseminated intravascular coagulation and cerebral involvement who do not respond to or deteriorate during standard treatment.
VovesC., WuilleminW.A., ZeerlederS.International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients.Blood Coagul Fibrinolysis2006; 17: 445–451.
2.
BremanJ.G.The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden.Am J Trop Med Hyg2001; 64: 1–11.
3.
KainK.C., KeystoneJ.S.Malaria in travelers. Epidemiology, disease, and prevention.Infect Dis Clin North Am1998; 12: 267–284.
4.
BlumbergL., LeeR.P., LipmanJ., BeardsS.Predictors of mortality in severe malaria: a two year experience in a non-endemic area.Anaesth Intensive Care1996; 24: 217–223.
5.
LosertH., SchmidK., WilfingA., WinklerS., StaudingerT., KletzmayrJ.Experiences with severe P. falciparum malaria in the intensive care unit.Intensive Care Med2000; 26: 195–201.
6.
Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster.Trans R Soc Trop Med Hyg2000; 94: 1–90.
HemmerC.J., KernP., HolstF.G., RadtkeK.P., EgbringR., BierhausA.Activation of the host response in human Plasmodium falciparum malaria: relation of parasitemia to tumor necrosis factor/cachectin, thrombin-antithrombin III, and protein C levels.Am J Med1991; 91: 37–44.
9.
VogetsederA., OspeltC., ReindlM., SchoberM., SchmutzhardE.Time course of coagulation parameters, cytokines and adhesion molecules in Plasmodium falciparum malaria.Trop Med Int Health2004; 9: 767–773.
10.
LaterreP-F, AbrahamE., JanesJ.M., TrzaskomaB.L., CorrellN.L., BoothF.V.ADDRESS (Administration of Drotrecogin Alfa [activated] in Early Stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation.Crit Care Med2007; 35: 1457–1463.
11.
MaciasW.L., YanS.B., WilliamsM.D., UmS.L., SanduskyG.E., BallardD.W.New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).Crit Care2005; 9: S38–45.
12.
BernardG.R., VincentJ.L., LaterreP.F., LaRosaS.P., DhainautJ.F., Lopez-RodriguezA.Efficacy and safety of recombinant human activated protein C for severe sepsis.N Engl J Med2001; 344: 699–709.
13.
KendrickB.J.L., GrayA.G., PickworthA., WattersM.P.R.Drotrecogin alfa (activated) in severe falciparum malaria.Anaesthesia2006; 61: 899–902.
14.
NjugunaP., NewtonC.Management of severe falciparum malaria.J Postgrad Med2004; 50: 45–50.
15.
RankinL.G., AustinD.L.H.The use of activated protein C in severe Plasmodium falciparum malaria.Anaesth Intensive Care2007; 35: 428–432.
16.
SrinivasR., AgarwalR., GuptaD.Severe sepsis due to severe falciparum malaria and leptospirosis co-infection treated with activated protein C.Malar J2007; 6: 42.
17.
NauA., PeytelE., PetrognaniR.Is there a place for activated protein C (Xigris) in the treatment of severe imported malaria in the adult?Ann Fr Anesth Reanim2006; 25: 1085–1086.
18.
BruneelF., HocquelouxL., LegrielS., BedosJ-P, WolffM.Activated protein C (Xigris) during severe imported malaria: look at benefit/risk ratio.Ann Fr Anesth Reanim2007; 26: 263–264.
